267 results on '"Malek, Ehsan"'
Search Results
2. A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia
3. Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies
4. Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma
5. Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma
6. Diffuse Large B Cell Lymphoma in Patients 80 Years and Older: Worse Survival After Treatment Without Increased Relapse Rates
7. Significant costs and low utilization of stored peripheral blood stem cells for salvage autologous transplant in multiple myeloma patients including those meeting mSMART criteria
8. Racial and age-related disparities in early mortality affect the outcomes of multiple myeloma patients
9. Novel therapies emerging in oncology to target the TGF-β pathway
10. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial
11. Gastrointestinal Microbiome and Mycobiome Changes during Autologous Transplantation for Multiple Myeloma: Results of a Prospective Pilot Study
12. Immune Signatures Associated With Clonal Isotype Switch After Autologous Stem Cell Transplantation for Multiple Myeloma
13. Comparison of Peripheral Blast Clearance and Day 14 Bone Marrow Biopsy in Predicting Remission Status and Survival After 7+3 Induction in Acute Myeloid Leukemia
14. MM-210 Targeting Proteasome-Dependent Antigen Presentation to Enhance T Cell–Mediated Tumor Killing
15. Targeted Marrow Irradiation Intensification of Reduced-Intensity Fludarabine/Busulfan Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation
16. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy
17. Physical Activity and Sleep Measures Using a Fitness Tracking Device during Hematopoietic Cell Transplantation: A Pilot Study
18. Myeloid-derived suppressor cells: The green light for myeloma immune escape
19. Multicenter Phase I Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leukemia
20. Impact of Visceral Obesity on Clinical Outcome and Quality of Life for Patients with Multiple Myeloma: A Secondary Data Analysis of STaMINA (BMT CTN 0702) Trial
21. Leveraging Artificial Intelligence to Uncover Hidden Biases in Survival Disparities of Patients with Multiple Myeloma
22. Assessing the Stanford Integrated Psychosocial Assessment for Transplantation (SIPAT) in Risk-Stratifying Multiple Myeloma Patients for Autologous Stem Cell Transplantation
23. PSMC2 Overexpression Enhances Proteasome Activity, Mitigates ER Stress, and Correleates with Reduced Overall Survival in Multiple Myeloma
24. Vactosertib, a Novel TGFb Type I Receptor Kinase Inhibitor, Improves T-Cell Fitness:a Single-Arm, Phase 1b Trial in Relapsed/Refractory Multiple Myeloma
25. An Immunoproteasome Activator That Increases MHC Class I Antigen Presentation to Enhance Anti-Tumor Immunity
26. Utilizing a Machine Learning Approach to Define Racial Difference in Multi-Systemic Impact of Monoclonal Protein in Patient with Multiple Myeloma
27. Assessing a New Paradigm in Defining High Risk Precursor Disease State for Patients with Plasma Cell Dyscrasia: Fluctuating Monoclonal Protein
28. GEN3014 (HexaBody ®-CD38) in Anti-CD38 Mab-Naive Patients with Relapsed/Refractory Multiple Myeloma: Preliminary Results from a Dose-Expansion Cohort of a Phase 1/2 Trial
29. Immune Profiling and Responses of Smoldering Multiple Myeloma Patients Treated in a Phase Ib Study of Pvx-410 Vaccine Targeting XBP1/CD138/CS1 Antigens, and Citarinostat, a Histone Deacetylase Inhibitor (HDACi) with and without Lenalidomide
30. P-185 Discovery of novel proteasome activators that enhance antigen presentation and trigger anti-myeloma T-cell immunity
31. P-186 Proteasome regulatory ATPase PSMC2 promotes drug resistance by mitigating ER stress and portends reduced overall survival in multiple myeloma
32. P-050 GEN3014 (HexaBody-CD38) versus daratumumab in patients with relapsed/ refractory multiple myeloma: design of randomized head-to-head expansion cohort of phase 1/2 trial
33. P-020 Dendritic cell/myeloma fusion vaccine with lenalidomide maintenance following autologous hematopoietic cell transplant (HCT) results in long-term sustained T cell activation and clonotypic expansion
34. MM-537 Impact of Melphalan Dose and CD34+ Cell Infusion on Engraftment and Post-Transplant Complications in Multiple Myeloma (MM) Patients
35. MM-506 Novel Proteasome Activators That Enhance MHC Class I Antigen Presentation and Trigger Anti-Myeloma T-Cell Immunity
36. MM-501 Overexpression of Proteasome PSMC ATPases Mitigates ER Stress and Correlates With Reduced Overall Survival in Multiple Myeloma
37. MM-514 Vactosertib, a Novel Transforming Growth Factor Beta (TGFß) Type I Receptor Kinase Inhibitor, Improves T-Cell Fitness: A Single-Arm, Phase Ib Trial in Relapsed or Refractory Multiple Myeloma (RRMM)
38. POSTER: MM-514 Vactosertib, a Novel Transforming Growth Factor Beta (TGFß) Type I Receptor Kinase Inhibitor, Improves T-Cell Fitness: A Single-Arm, Phase Ib Trial in Relapsed or Refractory Multiple Myeloma (RRMM)
39. POSTER: MM-537 Impact of Melphalan Dose and CD34+ Cell Infusion on Engraftment and Post-Transplant Complications in Multiple Myeloma (MM) Patients
40. POSTER: MM-506 Novel Proteasome Activators That Enhance MHC Class I Antigen Presentation and Trigger Anti-Myeloma T-Cell Immunity
41. POSTER: MM-501 Overexpression of Proteasome PSMC ATPases Mitigates ER Stress and Correlates With Reduced Overall Survival in Multiple Myeloma
42. Health Care Burden of Monogammopathy of Renal Significance
43. Development of a Machine Learning Algorithm for Rapid, Point-of-Care Prediction of Serum Monoclonal Proteins in Multiple Myeloma
44. A New Reality for Multiple Myeloma Renal Failure: US Data Report on Kidney Transplant Outcomes.
45. 542 - Dose Adjustment of Melphalan Is Safe and Effective for Certain Patients with MM Undergoing ASCT
46. 533 - Impact of Visceral Obesity on Clinical Outcome and Quality of Life for Patients with Multiple Myeloma: A Secondary Data Analysis of Stamina Trial
47. Contributors
48. Chapter 58 - Pharmacology and Molecular Mechanisms of Antineoplastic Agents for Hematologic Malignancies
49. Dynamics and Predictive Value of T-Cell Chimerism after Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide
50. A Tool to Longitudinally Assess the Secretory Capacity of Myeloma Cells throughout the Course of Disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.